These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16284537)

  • 21. Evaluation of attitude, risk behavior and expectations among Thai participants in Phase I/II HIV/AIDS vaccine trials.
    Maek-A-Nantawat W; Pitisuttithum P; Phonrat B; Bussaratid V; Naksrisook S; Peonim W; Thantamnu N; Muanaum R
    J Med Assoc Thai; 2003 Apr; 86(4):299-307. PubMed ID: 12757073
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 prophylactic vaccine trials in Thailand.
    Pitisuttithum P
    Curr HIV Res; 2005 Jan; 3(1):17-30. PubMed ID: 15638720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of increased HIV risk behavior among injection drug users participating in the AIDSVAX B/E HIV vaccine trial in Bangkok, Thailand.
    van Griensvan F; Keawkungwal J; Tappero JW; Sangkum U; Pitisuttithum P; Vanichseni S; Suntharasamai P; Orelind K; Gee C; Choopanya K;
    AIDS; 2004 Jan; 18(2):295-301. PubMed ID: 15075548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Knowledge, attitudes, and practices regarding antiretroviral management, reproductive health, sexually transmitted infections, and sexual risk behavior among perinatally HIV-infected youth in Thailand.
    Lolekha R; Boon-Yasidhi V; Leowsrisook P; Naiwatanakul T; Durier Y; Nuchanard W; Tarugsa J; Punpanich W; Pattanasin S; Chokephaibulkit K
    AIDS Care; 2015; 27(5):618-28. PubMed ID: 25506754
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predicting hypothetical willingness to participate (WTP) in a future phase III HIV vaccine trial among high-risk adolescents.
    Giocos G; Kagee A; Swartz L
    AIDS Behav; 2008 Nov; 12(6):842-51. PubMed ID: 17668313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Willingness to participate in HIV-1 vaccine trials among young Thai men.
    Jenkins RA; Torugsa K; Markowitz LE; Mason CJ; Jamroentana V; Brown AE; Nitayaphan S
    Sex Transm Infect; 2000 Oct; 76(5):386-92. PubMed ID: 11141858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand.
    Pitisuttithum P; Choopanya K; Bussaratid V; Vanichseni S; van Griensven F; Phonrat B; Martin M; Vimutsunthorn E; Sangkum U; Kitayaporn D; Tappero JW; Heyward W; Francis D
    J Med Assoc Thai; 2007 Nov; 90(11):2442-8. PubMed ID: 18181333
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric HIV type 1 vaccine trial acceptability among mothers in Kenya.
    Farquhar C; John-Stewart GC; John FN; Kabura MN; Kiarie JN
    AIDS Res Hum Retroviruses; 2006 Jun; 22(6):491-5. PubMed ID: 16796522
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A social vaccine? Social and structural contexts of HIV vaccine acceptability among most-at-risk populations in Thailand.
    Newman PA; Roungprakhon S; Tepjan S; Yim S; Walisser R
    Glob Public Health; 2012; 7(9):1009-24. PubMed ID: 22780324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV-1 risk and vaccine acceptability in the Ugandan military.
    Hom DL; Johnson JL; Mugyenyi P; Byaruhanga R; Kityo C; Louglin A; Svilar GM; Vjecha M; Mugerwa RD; Ellner JJ
    J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Aug; 15(5):375-80. PubMed ID: 9342258
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/E.
    Rerks-Ngarm S; Paris RM; Chunsutthiwat S; Premsri N; Namwat C; Bowonwatanuwong C; Li SS; Kaewkungkal J; Trichavaroj R; Churikanont N; de Souza MS; Andrews C; Francis D; Adams E; Flores J; Gurunathan S; Tartaglia J; O'Connell RJ; Eamsila C; Nitayaphan S; Ngauy V; Thongcharoen P; Kunasol P; Michael NL; Robb ML; Gilbert PB; Kim JH
    J Infect Dis; 2013 Apr; 207(8):1195-205. PubMed ID: 22837492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Response to Willingness to participate and enroll in a phase 3 preventive HIV-1 vaccine trial.
    Halpern SD
    J Acquir Immune Defic Syndr; 2003 Jul; 33(3):412. PubMed ID: 12843757
    [No Abstract]   [Full Text] [Related]  

  • 33. Personal experiences following acquiring HIV infection while volunteering in Phase I/II HIV vaccine trials: A qualitative study from Tanzania.
    Tarimo EAM; Ambikile J; Munseri P; Bakari M
    PLoS One; 2022; 17(10):e0276404. PubMed ID: 36288332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recruiting volunteers for a multisite phase I/II HIV preventive vaccine trial in Thailand.
    Thapinta D; Jenkins RA; Morgan PA; Chiu J; Boenim W; Bussaratid V; Chaddic C; Naksrisook S; Phonrat B; Sirijongdee N; Sornsathapornkul P; Sontirat A; Srisaengchai P; Suwanarach C; Wongkamhaeng S; Brown AE; Khamboonruang C; Nitayaphan S; Pitisuttithum P; Thongchareon P;
    J Acquir Immune Defic Syndr; 2002 Aug; 30(5):503-13. PubMed ID: 12154341
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in HIV vaccine acceptability between genders.
    Kakinami L; Newman PA; Lee SJ; Duan N
    AIDS Care; 2008 May; 20(5):542-6. PubMed ID: 18484322
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acceptability of HIV vaccine trials in high-risk heterosexual cohorts in Mombasa, Kenya.
    Jackson DJ; Martin HL; Bwayo JJ; Nyange PM; Rakwar JP; Kashonga F; Mandaliya K; Ndinya-Achola JO; Kreiss JK
    AIDS; 1995 Nov; 9(11):1279-83. PubMed ID: 8561982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group.
    Keefer MC; Wolff M; Gorse GJ; Graham BS; Corey L; Clements-Mann ML; Verani-Ketter N; Erb S; Smith CM; Belshe RB; Wagner LJ; McElrath MJ; Schwartz DH; Fast P
    AIDS Res Hum Retroviruses; 1997 Sep; 13(14):1163-77. PubMed ID: 9310283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HIV gp120 vaccine - VaxGen: AIDSVAX, AIDSVAX B/B, AIDSVAX B/E, HIV gp120 vaccine - Genentech, HIV gp120 vaccine AIDSVAX - VaxGen, HIV vaccine AIDSVAX - VaxGen.
    Adis International Ltd
    Drugs R D; 2003; 4(4):249-53. PubMed ID: 12848591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-vaccine research and development in Thailand: evolution and challenges.
    Pitisuttithum P; Choopanya K; Rerk-Ngnam S
    Vaccine; 2010 May; 28 Suppl 2():B45-9. PubMed ID: 20510743
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sexual Behaviours and Practices before and after Phase I/II HIV Vaccine Trial: A Qualitative Study among Volunteers in Dar es Salaam Tanzania.
    Iseselo MK; Tarimo EAM; Sandstrom E; Kulane A
    Int J Environ Res Public Health; 2020 Oct; 17(19):. PubMed ID: 33019597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.